New hope for kids with brittle bones: experimental drug faces off against standard care

NCT ID NCT06079372

Ongoing Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new medicine, ALXN1850, to the current standard treatment (asfotase alfa) in 43 children aged 2 to 12 with hypophosphatasia, a rare genetic condition that weakens bones. All children have been on the standard treatment for at least 6 months before joining. The main goal is to see if the new drug is safe and tolerable. Researchers will also check bone healing, rickets severity, and walking ability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypophosphatasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOPHOSPHATASIA

Contacts and locations

Locations

Research Site

Hartford, Connecticut, 06106, United States
Research Site

Baltimore, Maryland, 21287, United States
Research Site

Minneapolis, Minnesota, 55455, United States
Research Site

Kansas City, Missouri, 64108, United States
Research Site

Durham, North Carolina, 27705, United States
Research Site

Nashville, Tennessee, 37212, United States
Research Site

Mar del Plata, B7600, Argentina
Research Site

South Brisbane, 4101, Australia
Research Site

Ottawa, Ontario, K1H 8L1, Canada
Research Site

Bunkyō City, 113-8431, Japan
Research Site

Minatoku, 105-8471, Japan
Research Site

Suita-shi, 565-0871, Japan
Research Site

Yonago-shi, 683-8504, Japan
Research Site

Altındağ, 06230, Turkey (Türkiye)
Research Site

Ankara, 06560, Turkey (Türkiye)
Research Site

Edirne, 22030, Turkey (Türkiye)
Research Site

Erzurum, 25240, Turkey (Türkiye)
Research Site

Istanbul, 34899, Turkey (Türkiye)
Research Site

Birmingham, B4 6NH, United Kingdom
Research Site

Manchester, United Kingdom
Research Site

Sheffield, S10 2TH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.